Health and Healthcare

Potential Deathblow for Chelsea (CHTP)

Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) is being beaten hard this morning.  News hit that the FDA has now rejected the company’s Northera drug to treat low blood pressure for now in a complete response.  Effectively the FDA is asking Chelsea to provide more efficacy data.

Sadly, this could actually create a one or two year delay and the company was worth only $246 million before the news impact.  Chelsea has said that it still needs to have discussions with the FDA so that it can satisfy the FDA’s request.

The company believes that an ongoing trial might meet the FDA’s criteria but it is not sure if the FDA will require changes to the primary endpoint of Northera.  Unfortunately this is still just unfinished business.

Investors are shooting first and asking questions later.  Shares are down 28% at $2.62 in pre-market trading and the 52-week trading range is $2.18 to $6.06.  The NASDAQ pre-market trading alert has already gone over 800,000 shares and it is worth noting that the most recent short interest was at a yearly high of 7.26 million shares as of the March 15 settlement date.

The company is pre-revenue and it had about $45 million in liquidity at the end of the 2011 year.

JON C. OGG

The #1 Thing to Do Before You Claim Social Security (Sponsor)

Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.

A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.

Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.

 

Have questions about retirement or personal finance? Email us at [email protected]!

By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.

By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.